Cooley advised Triphase Accelerator Corporation in its partnership and option-to-acquire arrangement with Celgene to advance a pre-clinical therapeutic developed to treat leukemia and other blood cancers. Under the terms of the agreement, Triphase received an upfront payment of $40 million and, upon exercise of the option, will be eligible to receive up to $940 million in contingent development, regulatory and sales milestones.
